Owkin, a NYC-based predictive analytics company that utilizes transfer learning to accelerate drug discovery and development, raised $11m in Series A funding.
The round, which brings total financing to $13.1m, was led by Otium Venture with participation from Cathay Innovation, Plug and Play, and NJF Capital. In conjunction with the funding, Bruno Raillard, partner at Otium Venture, will join Owkin’s Board of Directors, which currently includes co-founders Gilles Wainrib, Ph.D. and Thomas Clozel, M.D., and NJF Capital founder Nicole Junkermann.
The company will use the funds to scale its platform, OWKIN Socrates, close additional partnerships with healthcare organizations, and accelerate internal growth.
Led by Thomas Clozel, M.D., CEO, Owkin provides Owkin Socrates, which allows pharmaceutical researchers at the preclinical and clinical trial phase, as well as hospital physician-researchers to leverage machine learning-based modeling to analyze molecular and imaging libraries as well as patient datasets to uncover complex biomarker patterns that cause disease.
The company partners with leading pharmaceutical companies including Amgen and Actelion and the company has programs in development with Institut Curie, Centre Leon Berard and Saint Louis Hospital.